Titan Pharmaceuticals (TTNP)
(Delayed Data from NSDQ)
$7.75 USD
+0.67 (9.46%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $8.86 +1.11 (14.32%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Titan Pharmaceuticals, Inc. [TTNP]
Reports for Purchase
Showing records 81 - 100 ( 113 total )
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Research Coverage of TTNP Under Review
Provider: BRINSON PATRICK SECURITIES CORPORATION
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Moving to Market Outperform: Pathway to Approval Becoming Clearer.
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Despite Positive Panel Recommendation, FDA Issues Complete Response Letter
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Panel Recommends Approval of Probuphine
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Advisory Committee Releases Briefing Documents on Probuphine
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INITIATION: An Opioid Addiction Drug - Probuphine Implant, Poised for Approval
Provider: BRINSON PATRICK SECURITIES CORPORATION
Analyst: HIGGINS M
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Titan Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are placing Titan Pharmaceuticals under review due to the departure from the firm of covering analyst
Provider: RODMAN & RENSHAW, CO.